We previously used a similar approach to analyze the LMr secretome derived from nasopharyngeal carcinoma cell lines, and successfully identified CCL5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma23. This evidence concerns the gene CCL5 and nasopharyngeal carcinoma.